Early diagnosis of cancer is crucial for successful treatment. Noninvasive assays for detecting tumor-derived antigens in serum and other bodily fluids have the potential to screen healthy individuals for hitherto undetected cancers. Very few such assays have been successfully developed, in part because identifying potential target antigens remains a challenge. To identify new blood-borne tumor antigens for the purpose of establishing such assays, we have developed a novel technique called differential immunization. Using this method, we have identified PHB1 and PHB2, proteins thought to function as mitochondrial chaperones and transcriptional regulators, as antigens released from colorectal tumors in vivo. Serum from colorectal patients contains significantly higher levels of these antigens compared to serum from healthy volunteers. These data demonstrate that differential immunization is an effective new method for identifying tumor-derived antigens in serum.
Introduction
Tumor cells are known to shed or secrete a variety of substances into the blood stream. A golden rule in oncology is that early detection of tumors is a critical factor for successful cancer treatment. There has therefore been much interest in developing simple assays for detecting tumor-derived antigens in the blood that might permit the detection of occult tumors in apparently healthy people. Furthermore, such assays should be useful clinically for assessing tumor burden, for example during therapy, or for monitoring of renewed tumor growth for patients in remission.
To date, only a very few assays for serum-borne antigens are in widespread clinical use. The most wellknown of these detects serum-borne prostate-specfic antigen (PSA), a secreted serine protease, for the early detection of prostate neoplasia (reviewed in Bangma and Verhagen, 2000) . In addition, a variety of other proteins, including additional serine proteases, are shed or secreted by prostate tumors and their detection may have utility in the monitoring of this disease (Bok and Small, 2002) . There has been considerable interest in CA-125 antigen as a serum-borne marker of ovarian cancer, but it is currently thought that assessment of CA-125 levels in the serum is not adequate as a screening method for this malignancy (Maggino and Gadducci, 2000; Ardekani et al., 2002) . The utility of measuring serum levels of several adhesion and other cell-surface molecules shed by tumors is currently being investigated. For example, preoperative serum levels of Her-2/neu have some prognostic significance (Molina et al., 1996; Bast et al., 2001) . Carcinoembryonic antigen (CEA) is shed by many colorectal tumors into the blood stream, but while monitoring of CEA level in serum has some utility in postoperative follow-up, it is not useful as a primary screening method (Bast et al., 2001) .
Clearly, new screening methods for the detection of occult tumors in apparently healthy individuals are required. However, discovering new targets that can be used in diagnostic assays is a major challenge. To identify antigens shed or secreted from human tumors into the blood stream that might serve as targets for diagnostic assays, we have developed the technique of differential immunization (DI; Figure 1a ). In DI, human tumor cells are injected subcutaneously into BalbC nude mice and tumors are allowed to grow to the maximum legal limit. The animals are then killed and bled out using cardiac puncture. Serum produced from this blood is then used for immunizing immunocompetent BalbC mice. An immune reaction only occurs against antigens derived from the human tumor cells because the other serum components are derived from animals that come from the same genetic background (i.e. BalbC). A further important component of this method is the regional subcutaneous injection of antigen to provoke a local immune response in the regional lymph nodes rather than a systemic response in the spleen. Lymph nodes rather than spleens are used as the source of lymphocytes for subsequent hybridoma formation. This has several advantages: (i) very small amounts of antigen are required (ii) immunization is rapid (iii) tolerance against conserved antigens can be broken.
To test whether the concept of DI works, we used DI to look for antigens shed or secreted by human colorectal tumor cells. We chose to use COLO 320DM tumor cells, because these cells express no CEA, an antigen already known to be shed from many colorectal tumor cells (see ATCC entry for COLO 320DM cells, Accession No. CCL-220).
We reasoned that at least a proportion of shed or secreted antigens might be found on the cell surface. Thus, we screened the supernatants of hybridomas resulting from DI with COLO 320DM cells using whole cell ELISA assays. Thereby, we identified three hybridomas that produced antibodies strongly able to recognize antigens expressed on the surface of COLO 320DM cells (Figure 1b) . Several other hybridomas produced antibodies that bound weakly to COLO 320DM cells in cell ELISAs.
To identify the antigens bound by the three DIproduced antibodies that bound strongly to COLO 320DM cells, we next screened to see which of them could be used for affinity purification of the respective antigen. To this end, we first surface-biotinylated COLO 320DM cells and used them in immunoprecipitation analyses with the antibodies. One of the antibodies (1C1) was able to immunoprecipitate a pair of cell surface proteins of molecular weight of about 32 and 37 kDa from lysates of surface-biotinylated COLO 320DM cells (Figure 2a ). We therefore focused on the 1C1 antibody because it was the only one of the three that functioned well in immunoprecipitation assays, facilitating the affinity-purification of the corresponding antigen and its subsequent identification. None of the antibodies functioned in Western blots (data not shown).
The 1C1 antibody was next used to produce an affinity column for purification of the two proteins to which it binds. Proteins eluted from the affinity column were separated by SDS-PAGE and the resulting gels were silver stained to visualize the purified proteins ( Figure 2b ). The two proteins of 32 and 37 kDa were then eluted from the gel and subjected to MALDI TOF analysis. This identified the 32 kDa protein as PHB1 (prohibitin) and the 37 kDa protein as the closely related PHB2 (BAP37).
To prove the identity of the two proteins bound by the 1C1 antibody, we immunoprecipitated COLO 320DM lysates using the 1C1 antibody and ran the precipitates on a SDS-PAGE gel. The gel was then Western blotted and probed with a commercially available anti-PHB1/PHB2 antibody ( Figure 2c ). This demonstrated that the proteins immunoprecipitated by the 1C1 antibody were recognized by established PHB1/ PHB2 antibodies, proving their identity as PHB1/PHB2.
To determine the extent of expression of PHB1 and PHB2 in human colorectal and other carcinomas, we used the 1C1 antibody to stain sections of 12 different tumor types ( Figure 3 , Table 1 ). Positive 1C1 staining was observed in the cytoplasm of a large proportion of both colorectal tumors and other types of cancer. Membrane staining may also be present, but we could not easily distinguish this from the extensive cytoplasmic staining. No nuclear staining was observed. Consistently, immunofluorescence staining of permeabilized COLO 320DM cells with the 1C1 antibody demonstrated that in addition to cytoplasmic staining Nude Balb/C mice are injected with human tumor cells. The tumor is allowed to grow and then blood is taken. Serum produced from this blood is used to immunize wild-type Balb/C mice. Lymphocytes from popliteal lymph nodes are then fused with myeloma cells to generate antibody-producing hybridomas. (b) DI using COLO 320DM cells generates antibodies that bind to COLO 320DM cells in cell ELISA assays. COLO 320DM cells (1 Â 10 6 ) (ATCC Accession No.: CCL-220) were injected subcutaneously in BalbC nude mice. When the tumors reached the German legal limit, mice were killed and blood was taken by cardiac puncture to obtain serum. Immunization of normal BalbC mice with 25 ml of this serum was performed six times over a period of 17 days using the method of local subcutaneous injection (Niebuhr et al., 1998) . After the immunization procedure the mice were killed and the popliteal lymph nodes were taken. The lymph nodes were mashed through a sterile 40 mm nylon filter (Falcon) and the single cell suspension of lymphocytes so obtained was used for hybridoma formation. Hybridomas were made by using the 30% PEG spinning method (Harlow and Lane, 1998) to fuse SP2/0 myeloma cells (ATCC Accession No.: CRL-1581) to the lymphocytes. Hybridoma supernatants were tested in a cell ELISA assay (Sleeman et al., 1999) using COLO 320DM cells as targets. Selected examples of different hybridoma clones are shown (row 1). For a positive control ( þ ), cells were incubated with 10 mg/ml of the anti-CD44 monoclonal antibody Hermes3 instead of conditioned medium (row 4). For a negative control (À), cells were incubated with PBS/10% FCS (row 4) PHB1/PHB2 are blood-borne tumor antigens J Mengwasser et al reminiscent of the mitochondrial staining pattern previously reported with other PHB1/PHB2 antibodies, a proportion of the staining was membrane-associated ( Figure 4a ). Again, no nuclear staining was observed.
The immunohistochemistry data demonstrate that PHB1 and PHB2 expression is not limited to COLO 320DM tumor cells, but more broadly in many colorectal tumors. This notion is also supported by the observation in cell ELISA analysis of a panel of colorectal carcinoma cell lines, in which other colorectal tumor cell lines were found to be positively stained by the 1C1 antibody (Figure 4b ). The immunohistochemistry data also suggest that PHB1/PHB2 may be shed or secreted by other tumor types in addition to colorectal neoplasias, as many tumors types were stained positively with the 1C1 antibody.
Using the 1C1 antibody and commercially available antibodies against PHB1/PHB2, we developed a sandwich ELISA assay for PHB1 and PHB2. This permitted us to show that contrary to serum from control nontumor-bearing animals, serum from COLO 320DM tumor-bearing animals contains significant levels of human PHB1/PHB2 (Figure 4c ). We also used the ELISA assay to compare serum samples that were obtained after informed consent from colorectal patients and healthy volunteers (Figure 4d ). The data show that the serum samples from the tumor patients contained significantly higher levels of prohibitin/BAP37 compared to those from the healthy volunteers. Together, these data prove the principle that DI can be used to generate antibodies against antigens shed or secreted by human tumor cells.
PHB1 and PHB2 (also called prohibitin 1/2 and BAP 32/37) are two closely related proteins that are highly conserved among different species and belong to a family of proteins that include stomatins, HflKC, flotillins and plant defence proteins (reviewed in Nijtmans et al., 2002) . PHB1 and PHB2 form a multimolecular complex in the inner membrane of mitochondria where they are thought to function as molecular chaperones (Nijtmans et al., 2000) . A mitochondrial function for these proteins is also suggested by observations linking loss of PHB1 and PHB2 with senescence and aging (Liu et al., 1994; Coates et al., 2001; Piper and Bringloe, 2002) .
Further molecular functions and locations for PHB1 and PHB2 are currently debated. It has been reported that a subset of these proteins can be found in the nucleus, where they colocalize with Rb, repress E2F-mediated transcription and suppress cell growth (Wang et al., 1999a (Wang et al., , b, 2002a Fusaro et al., 2002) . PHB1 and antibody immunoprecipitates a doublet of proteins labelled by surface biotinylation. The isotype of the 1C1 antibody was found to be IgM using the IsoStrip kit (Roche). COLO320DM cells were washed three times with PBS, incubated with 1 mg Sulfo-NHS-LCBiotin (Pierce, Rockford) in PBS on ice for 1 h to label cell surface proteins, then harvested with PBS/5 mM EDTA, then lysed with immunoprecipitation lysis buffer (1% Triton X-100 in PBS, 20 mM PSMF) for 20 min on ice and centrifuged to remove the debris. The supernatant was precleared with protein-L agarose beads. Aliquots of supernatant were then incubated with 10 mg of 1C1 antibody or 10 mg of a mouse IgM control antibody for a control (Sigma, Munich, Germany) together with 100 ml of a 50% slurry of protein-L agarose beads. After rotation at 41C for 2 h, the beads were washed four times with lysis buffer, then mixed with 50 ml of SDS-PAGE sample buffer (2% SDS, 125 mM Tris-HCl, pH 6.8, 100 mM dithiothreitol, 10% glycerol). Immunoprecipitates were analysed by SDS-PAGE and Western blotting (Towbin et al., 1979) . Blots were probed with streptavidin coupled to HRP. Visualization of proteins on the blot was performed using the ECL detection system (Amersham, Freiburg). The doublet of proteins specifically bound by the 1C1 antibody is labelled with arrows. (b) Silver stained SDS-PAGE of proteins were immunoprecipitated with 200 ml of 50% slurry protein-L agarose from nonlabelled COLO320DM cells (1 Â 10 8 ) using 20 mg control antibodies (IgM), no antibodies (À) or 20 mg of the 1C1 antibody. The gel was silver stained without using glutaraldehye fixation using a silver staining kit (Amersham, Freiburg). The protein bands specifically immunoprecipitated by the 1C1 antibody were excised, then subjected to MALDI-TOF analysis by TOPLAB GmbH (Munich), which unequivocally identified the lower band as prohibitin and the upper as BAP37. The size of the molecular weight markers (M) is indicated. The doublet of proteins specifically bound by the 1C1 antibody is labelled with arrows. (c) Lysates of COLO 320DM cells were immunoprecipitated with the 1C1 antibody. The immunoprecipitate was then subjected to SDS-PAGE and Western blotted (1C1 I.P.). For controls, COLO 320DM lysate (lysate) and a 1C1 immunoprecipitation in which no lysate was added (control) were run on the gel in parallel. The blot was probed as previously described (Sleeman, 1993) with polyclonal anti-PHB antibodies (Ab-2, Neomarkers, Fremont), followed by anti-rabbit HRPconjugated antibodies. Visualization of proteins on the blot was performed using the ECL detection system (Amersham, Freiburg) PHB1/PHB2 are blood-borne tumor antigens J Mengwasser et al PHB2 have also been reported to interact with the IgM binding receptor (Terashima et al., 1994) and with the estrogen receptor (Montano et al., 1999) , but the physiological relevance of these findings has been questioned (Nijtmans et al., 2002) . More recently, PHB1 and PHB2 have been shown to form complexes with alpha-actinin and annexin A2 (Bacher et al., 2002) . Gastric carcinoma 6/9 ++/+++ Strong staining of cardiac glands 3/9 À/+ Esophagus SCC 8/9 ++/+++ Weak epithelial staining basally 1/9 À/+ Lung cancer 6/8 ++/+++ Alveoli and bronchi negative 2/8 À/+ Colorectal carcinoma 9/9 ++/+++ Crypts negative or weakly positive, moderate to strong staining on the luminal surface Thyroid papillary carcinoma 2/10 ++/+++ Epithelium generally negative, although some isolated areas showed moderate staining 2/10 À/+ Kidney RCC 6/8 ++/+++ Tubules moderately to strongly stained, glomerulus negative 2/8 À/+ Mammary carcinoma 6/10 ++/+++ Ductal epithelium moderately stained 4/10 À/+ Hepatic carcinoma 9/10 ++/+++ Lobules uniformly strongly stained 1/10 + Urinary bladder carcinoma 4/8 ++/+++ Epithelium weakly stained 4/8 À/+ Pancreatic carcinoma 8/10 ++/+++ Moderately stained throughout 2/10 À/+ Prostate carcinoma 6/9 ++/+++ Ductal epithelium moderately stained 3/9 À/+ À, no staining; +, weak staining; ++, moderate staining; +++, strong staining PHB1/PHB2 are blood-borne tumor antigens J Mengwasser et al
In agreement with the data we show here, PHB1 and PHB2 expression has been shown histologically to be upregulated in a variety of tumors (Coates et al., 2001 ).
Consistently, PHB1 and PHB2 have been reported to be highly expressed in a number of tumor cell lines (reviewed in Nijtmans et al., 2002) . This enhanced expression of PHB1 and PHB2 in tumors may possibly represent a response to increased anaerobic glycolysis in tumor cells (Nijtmans et al., 2002) , although it is interesting to speculate that it may serve to counteract the loss of PHB1 and PHB2 activity associated with senescence and aging.
What mechanism is responsible for the release of PHB1 and PHB2 from tumor cells into the blood? The current understanding of the molecular biology of PHB1 showing that PHB1/PHB2 can be detected in the serum of COLO320DM tumor-bearing mice but not in serum from control mice. Flat-bottom 96-well plates were coated overnight with 100 ml/ well of the 1C1 antibody (10 mg/ml in PBS). The wells were then blocked with 2% BSA in PBS and incubated for 1 h with mouse serum (diluted in 2% BSA/PBS where necessary), COLO 320DM lysate (5 Â 10 6 cells/ml in immunoprecipitation lysis buffer) or 2% BSA in PBS as appropriate. After washing the plate three times in PBS, the wells were incubated for 1 h with 100 ml of 10 mg/ml of polyclonal anti-PHB antibody (Ab-2, Neomarkers, Fremont) in 2% BSA/PBS. The plate was then washed four times with PBS, and color development was performed using ABTS. The extinction was measured at 405 nm in a 96-well plate reader. Serum from COLO 320DM tumor-bearing animals was used nondiluted (1) or was diluted 1 : 1, 1 : 2 or 1 : 4 (2-4). Serum from control animals was used nondiluted (5). Lysate from COLO320DM cells served as a positive control (6). PBS containing 2% BSA served as a negative control (7). (d) Box-whisker plots of data obtained using a sandwich ELISA assay for PHB1/PHB2 which shows that PHB1/ PHB2 can be detected at higher levels in the serum of colorectal tumor-bearing patients compared to the serum of healthy volunteers. Serum samples from 27 colorectal patients (Tumor) and 11 healthy volunteers (Normal) obtained after informed consent were compared using the sandwich ELISA assay for PHB1/PHB2 described in b, using the chemiluminescent Super Signal s ELISA Femto Maximum Sensitivity Substrate to develop the signal. The signals were detected on a Lambda Fluoro 320 (MWG) ELISA plate reader. The boxes show the 75th, 50th and 25th percentiles, while the whiskers show the 95th and 5th percentiles. The data were statistically compared using the t-test, which showed that the serum samples from the tumor patients showed significantly higher levels of PHB1/PHB2 (Po0.01 at 20 degrees of freedom). The colorectal cancer patients were between 44-and 85-year old, median age 67-year old. Equal numbers of male and female patients were selected. Serum samples were taken preoperatively. Three of the patients had rectal tumors, eight had sigmoid tumors, the remaining had tumors of the ascending, transverse or descending colon. In all, 10 of the patients had nonmetastatic disease, the remaining had metastatic disease and PHB2 does not permit this question to be answered. There are precedents for altered subcellular localization of mitochondrial proteins to the plasma membrane, for example through phosphorylation or alternative splicing Bhagwat et al., 1999; Huang et al., 1999) , but to date, we do not have evidence to support such regulation for PHB1 and PHB2. The fact that the 1C1 antibody detects PHB1/ PHB2 in cell ELISA assays (Figures 1b and 4b) , that PHB1/PHB2 are labelled in surface biotinylation assays (Figure 2a) and that a proportion of 1C1 staining is membrane-associated in immunofluorescence studies on permeabilized COLO 320DM cells (Figure 4a ) suggests a partial cell surface localization for these proteins. This is the first time that such a localization has been detected for PHB1/PHB2 and suggests that shedding or secretion may account for the detection of these proteins in serum. We also cannot rule out the possibility that necrosis within tumors results in the release of PHB1/ PHB2 from dead cells into the blood. This question will be the focus of further investigations.
The 1C1 antibody we report here immunoprecipitates PHB1 and PHB2 and functions in cell ELISA assays, but does not work in Western blots (data not shown). As PHB1 and PHB2 form tight multivalent complexes that act to stabilize the constitutent monomers (Berger and Yaffe, 1998; Coates et al., 2001) , we therefore cannot at present determine whether the 1C1 antibody binds to both PHB1 and PHB2 or just to one of the proteins. The high amino-acid sequence conservation between the two proteins make it likely, however, that both PHB1 and PHB2 are bound by the 1C1 antibody.
In summary, the results presented here represent proof of principle that DI is a powerful method for identifying novel serum-borne tumor antigens. Such antibodies permit the identification of novel tumorderived antigens in serum, and the establishment of assays that may have clinical utility for diagnostic screening. Based on the success of DI, we plan to deploy the method more widely in the hope of developing assays that will assist in the early diagnosis of occult tumors and thereby improve the chances of curing cancer patients.
